ClinicalTrials.Veeva

Menu

Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery

University Hospitals (UH) logo

University Hospitals (UH)

Status

Terminated

Conditions

Hypovolemic Shock
Surgery
Trauma
Emergency

Treatments

Other: OPTIMIZED
Other: CONTROL

Study type

Interventional

Funder types

Other

Identifiers

NCT01653977
NAC 09-044

Details and patient eligibility

About

This study compares the safety and efficacy of GDTs using standard pressure-related parameters vs. dynamic hemodynamic indices associated with fluid compartment monitoring, in trauma patients requiring emergency surgery.

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults > 18 years
  • Severe hypovolemic condition°
  • Need for emergent interventional procedure under general anesthesia with an expected duration > 120 min.

Exclusion criteria

  • Patients responding to early fluid resuscitation (20ml/kg) who don't require a CVC
  • Neurotrauma (Glasgow Coma Score < 12) and/ or medullar trauma
  • Known pregnancy or diagnosed by US or Ct-scan (> 14 weeks)
  • Sustained cardiac arrhythmia (see Logbook P8)
  • Known or diagnosed severe cardiac valvular dysfunction (stenosis, insufficiency) (see Logbook P8)
  • Known or diagnosed intracardiac shunt: interventricular or atrial defect (see Logbook P8)
  • Burn injury > 10%
  • Needed emergency thoracotomy or ABC resuscitation protocol
  • Pre-existing severe liver dysfunction(Child-Pugh class C)
  • Do-not-resuscitate order, died within 48h of admission
  • Ultra-emergent surgery with no further diagnostic investigation.

Trial design

20 participants in 2 patient groups

CONTROL
Active Comparator group
Description:
In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
Treatment:
Other: CONTROL
OPTIMIZED
Active Comparator group
Description:
In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany). The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
Treatment:
Other: OPTIMIZED

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems